Roivant is one of the savviest dealmakers in biotech. It also has a secret weapon The success of the company’s lung disease drug in a mid-stage study is a testament to its approach

https://www.statnews.com/2026/09/10/roivant-biotech-dealmaking-mosliciguat-origins/ By Adam FeuersteinSept. 10, 2026 Senior Writer, Biotech